• Best Practices New Normal
  • Digital Dentistry
  • Data Security
  • Implants
  • Catapult Education
  • COVID-19
  • Digital Imaging
  • Laser Dentistry
  • Restorative Dentistry
  • Cosmetic Dentistry
  • Periodontics
  • Oral Care
  • Evaluating Dental Materials
  • Cement and Adhesives
  • Equipment & Supplies
  • Ergonomics
  • Products
  • Dentures
  • Infection Control
  • Orthodontics
  • Technology
  • Techniques
  • Materials
  • Emerging Research
  • Pediatric Dentistry
  • Endodontics
  • Oral-Systemic Health

Vivos Therapeutics’ Sleep Apnea mmRNA Oral Appliance Receives FDA Market Clearance


The sleep apnea appliance has received FDA market clearance which will allow it to be more widely used and covered by insurance.

Vivos Therapeutics’ Sleep Apnea mmRNA Oral Appliance Receives FDA Market Clearance

Vivos Therapeutics

Medical technology company Vivos Therapeutics has received 510(k) market clearance for its modified mandibular Repositioning Nighttime Appliance (mmRNA) in treatment of mild to moderate sleep-disordered breathing in adults.

Vivos Therapeutics specializes in research and development of treatment modalities for patients who deal with sleep apnea and other sleep-disordered breathing. The mmRNA is the latest modality granted clearance by the U.S. Food and Drug Administration (FDA). The FDA clearance will allow the device to be reimbursed by insurance coverage which includes Medicare. Kirk Huntsman, Vivos Chairman and CEO, said in a press release that this clearance will greatly improve the lives of those who suffer from sleep-disordered breathing.

“The FDA’s market clearance of Vivos’ newest device, the mmRNA appliance, represents a significant milestone in our ongoing efforts to provide the best possible treatment for people who continue to suffer needlessly from obstructive sleep apnea (OSA), a debilitating condition that causes or contributes to a wide range of chronic health issues,” Huntsman said in the press release.

With OSA being a problem for 1 billion people globally, Vivos’s aim is to serve those who suffer from this chronic illness through a range of oral appliances. According to the press release, patients treated with the Vivos System rarely require lifetime intervention after treatment.

In addition to this news, Vivos’s previously submitted DNA appliance has been denied by the FDA. Already registered with the FDA as a Class I device, this appliance will be resubmitted with an appeal of the FDA’s decision. The appliance is still usable, and Vivos is optimistic about future prospects and outcomes.

Related Videos
CDA 2024 Video Interview with Kuraray Noritake's Dinesh Weerasinghe and Richard Young, DDS
2024 Dental Products Report Spring Selection Bracket Reveal Video
Addressing Unmet Needs in Early Childhood Oral Care - an interview with Ashlet Lerman, DDS
2024 Chicago Dental Society Midwinter Meeting – Interview with Peter Maroon, business development and sales lead at Spectrum Solutions® on the new salivary diagnostic test, SimplyPERIO.
Product Bites – March 8, 2024 Part 2
Product Bites – March 8, 2024 Part 1
Contemporary Cosmetic Dentistry – Part II: Arresting Marginal Caries
GNYDM23 Product Focus: CandidPro with Kristin Lange, VP of Sales at Candid
Greater New York Dental Meeting 2023 – Interview with Suzanne Cano from LunaLite Dental
© 2024 MJH Life Sciences

All rights reserved.